reports
- Guy Sips
- Michiel Declercq
- Livio Luyten
Whitestone Group €70m capital raise at NAV backed by new Alcopa signal...
Whitestone announced a capital increase of approximately €70m in two phases to fuel its growth strategy. A first €46m private placement will be executed at €17.1ps (NAV as of 1H25), backed by main shareholders and new investor Alcopa (family Moorkens). This represents a 30% premium to yesterday's share price and underscores confidence in the company's trajectory. This is expected to be followed by a second ~€25m public offering in 2Q26 on the same terms, and will be open for “qualified investors...
- Wim Hoste
Umicore EU looks set to abandon combustion engine ban in 2035
Based on various press articles, it seems increasingly likely that the European Union is to abandon the earlier agreed ban on new combustion engine-based passenger cars by 2035, whilst new legislation would still require a significant reduction of tailpipe emissions. Any loosening of legislation would probably be good news for Umicore's Catalysts business, with European ICE Light duty Automotive Catalysts' revenue representing c. 28% of total ICE light duty Automotive Catalysts' revenue. We awai...
- Guy Sips
- Kristof Samoy
- Kristof Samoy
CMB.Tech Investment in Chinese ammonia supply
CMB.TECH is investing in the Chinese ammonia supply chain and signed an off-take agreement for green ammonia produced by CEEC in the Jilin Province and will own a minority share in privately owned Andefu, one of China's largest ammonia supply chain companies. While CMB.TECH did not disclose any financials on the deal we estimate linked financials are relatively small. CMB.TECH has a sensible but disciplined investment approach towards decarbonisation. Through the offtake agreement and terminal o...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Ontex Model update post profit warning
Ontex issued a severe profit warning which implies the company now expects 4Q25 adjusted EBITDA to land at € 38-43m vs a previous expectation range of € 63-68m, with the downwards revision due to intense competition from A-brands in the baby care segment. We have reduced our adjusted EBITDA forecasts for FY25-27 by between 8-10%, but still expect FY26 EBITDA to grow by c. 12% vs our new FY25 forecast, on a combination of efficiency measures, the full contribution of new contracts and (at some po...
- Jacob Mekhael
argenx Vyvgart phase 3 in TED stopped due to lack of efficacy
argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...
- Thomas Couvreur
ABN Amro NIBC, Wealth & Staff reductions drive value; target price inc...
We have reviewed our model on ABN Amro, incorporating the NIBC acquisition, the ambitious growth targets in Wealth Management and the aggressive cost savings targets, mainly driven by FTE reductions. By FY28 we see our income estimates increase by 4.3% and cost estimates decrease by 3.1%. Our new SoTP valuation points to a target price of €29 (vs €25.5), reiterating our Hold recommendation given limited upside.
- Wim Lewi
Care Property Invest Upgrade to Accumulate after rights issue and majo...
We like the pro-active nature of this deal. CPI completed a capital increase of €55.5m to finance the acquisition of 9 healthcare assets for €142.6m (announced on 3/12). The remaining €87.1m was financed by €47.1m new debt and €40m of existing debt at a low rate (2.9%). This deal will offset the overhang of the lease portfolio expiries for the next 10 years. Hence, CPI addresses a concern that has been weighing on the share price. The rights issue take-up amounted to 62.6%. We believe this is a ...
- Jacob Mekhael
Zealand Pharma CMD key takeaways
Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Kristof Samoy
Arcadis 26 year company veteran and GBA-head of Resilience to become n...
Arcadis has nominated Heather Polinsky as its next CEO, effective 1 March 2026, pending shareholder approval at the Annual General Meeting next May. Alan Brookes will step down earlier than expected, as his term was originally set to run until 2027. The leadership change is intended to reinvigorate growth and strengthen the company's market position ahead of its next strategic cycle. Arcadis has missed its organic growth targets from the 2023 CMD, with year-to-date topline growth in 2025 at only...
- Wim Hoste
Titan Acquisition of Traçim Cement
The acquisition of Turkish Traçim Cement for c. $ 190m equity value complements TITAN's existing Turkish footprint and increases flexibility in export possibilities, ao to the US. The acquisition also fits well within the Forward 2029 Strategic plan which was presented last month, and which targets to grow EBITDA by 62% to € 1bn by 2029 on a combination of organic growth initiatives and M&A in regions where the company has an established footprint and acquisitions offer sizeable synergies potent...
- Wim Lewi
Xior Feed Back from the Xior Analyst call on FY26 guidance-Correction
The surprise call on the outlook update was only open to analysts and basically served to highlight the past 10 years of growth. Nevertheless €2.30 EPRA EPS, comes above consensus and our €2.25 estimate. Xior wants to show that after 2 years of transition and flat EPS, they will show growth again. Under COO, Kristina Olsen, Xior has also improved its internal operations and budget planning for next year had already finished. The focus is on internal efficiency gains and rental growth from realis...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Wim Lewi
Xior Xior rings the bell with a FY26 EPRA EPS outlook of €2.30
Today Xior celebrates its 10 year listing on the Brussels stock exchange. At the same time it issued a FY26 EPRA EPS outlook and expects EPS growth of +4% in FY26 to €2.30 vs. FY25 of €2.21. Xior is confident about the future, driven by its student housing platform and 98% occupancy. It expects rental growth from additions to its scalable operations and structural market scarcity to drive rental increases. Also efficiency gains should add to profitability gains. Xior will focus on portfolio opti...
- Jacob Mekhael
- Mathijs Geerts Danau
Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...
Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...
- Wim Hoste
Ontex Profit warning, restructuring plan and new CEO appointment
Ontex just issued a profit warning revising its full-year outlook downwards. At the same time the board has decided to appoint Laurent Nielly , currently president of Ontex Europe, as the new CEO. The change will be effective as of May 2026 when the mandate of the current CEO comes to an end. The adjusted FY EBITDA25 guidance calls for a range of €175-€180m (previously €200-€210m) compared to KBC's forecast of €197m. Ontex's management is now accelerating an efficiency improvement initiative acr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.